Single-dose administration of factor VIIa

Details Single-dose administration of factor VIIa Single-dose administration of factor VIIa

2008-09-02

2008-09-02

Kosar, Andrew D. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S381000

Reexamination Certificate

active

10196902

ABSTRACT:
The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of Factor VIIa or a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 μg/kg Factor VIIa or Factor VIIa equivalent.

REFERENCES:
patent: 4404132 (1983-09-01), Mitra
patent: 5180583 (1993-01-01), Hedner
patent: 6310183 (2001-10-01), Johannessen et al.
patent: 6833352 (2004-12-01), Johannessen et al.
patent: 2006/0025336 (2006-02-01), Rojkjaer et al.
A Chuansumrit, et al. Haemophilia. (2000) 6, 61-65.
E Erhardtsen. Semin. Thromb. Hemost. (2000) 26, 385-391.
JM Lusher, et al. Haemophilia. (1998) 4, 790-798.
T Shafi, et al. Br. J. Haem. (1997) 98, 910-912.
M -C Poon, et al. Blood (1999) 94, 3951-3953.
B Jurlander, et al. Semin. Thromb. Hemost. (2001) 27, 373-383.
C Negrier and A Lienhart. Blood Coag. Fibrin. (2000) 11 (suppl 1), s19-s24.
P Petrini and G Klementz. Blood Coag. Fibrin. (1998) 9 (suppl 1), s143-s146.
J Inverslev, et al. Blood Coag. Fibrin. (1998) 9 (suppl 1), s07-s110.
CRM Hay, et al. Thromb. Haemost. (1997) 78. 1463-1467.
U Hedner. Haemostasis (1996) 26 (suppl 1). 102-108.
JM Lushner. Haemostasis (1996) 26 (suppl 1), 124-130.
R Kulkami, et al. Am. J. Hematol. (2001) 67, 240-246.
“NovoSeven” product insert. Novo Nordsik Pharmaceuticals, Inc. Issued Aug. 2004.
V. Diness, et al. Throm. Res. (1990), 59, pp. 921-929.
K.D. Butler, et al. Blood Coag. Fibrin. (1993) 4, pp. 459-464.
A.D. Shapiro, et al. Thromb. Hemost. (1998) 80(5), pp. 773-778.
L.B. Jaques and R.A. Mustard. Biochem. J. (1940) 34(2), pp. 153-158.
J.M. Lusher. Eur. J. Haematol. Suppl. (1998) 63, pp. 7-10.
J. Ingerslev. Haematologica. (2000) 85(10 suppl) 15-20.
Hedner, U.: Dosing and Monitoring NovoSeven® Treatment, Haemostasis 1996; 26 (suppl 1): 102-108.
Mayer, S.A., et al.: Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage, New England Journal of Medicine 2005; 352: 777-785.
Parameswaran, R., et al.: Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry, Haemophilia 2005; 11: 100-106.
Roberts, H.R.: Thoughts on the mechanism of action of FVIIa, 2ndSymposium on New Aspects of Hemophilia Treatment, Copenhagen, Denmark, 1991, pp. 153-156.
Butenas, S., et al.: Mechanism of factor VIIa-dependent coagulation in hemophilia blood, Blood 2002; 99: 923-930 Figure A Copyright American Society of Hematology used with permission.
Allen, G.A., et al.: The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation, Blood Coagulation and Fibrinolysis 2000; 11 (suppl 1): 3-7.
Lindley, C.M., et al.: Pharmacokinetics and pharmacodynamics of recombinant Factor VIIa, Clinical Pharmacology & Therapeutics 1994: 55(6); 638-648.
Bauer, K.A.: Treatment of Factor VII deficiency with recombinant Factor VIIa, Haemostasis 1996; 26 (suppl 1): 155-158.
Lusher, J., et al.: Clinical experience with recombinant Factor VIIa, Blood Coagulation and Fibrinolysis 1998; 9: 119-128.
Bech, M.R.: Recombinant Factor VIIa in Joint and Muscle Bleeding Episodes, Haemostasis 1996; 26 (suppl 1): 135-138.
Lusher, J.M.: Recombinant Factor VIIa (NovoSeven®) in the Treatment of Internal Bleeding in Patients with Factor VIII and IX Inhibitors, Haemostasis 1996; 26 (suppl 1): 124-130.
Lusher, J.M., et al.: A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with hemophilia A and B, with and without inhibitor, Haemophilia 1998; 4: 790-798.
Shapiro A.D., et al: Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery, Thrombosis and Haemostasis 1998; 80: 773-778.

Affiliated with

Also associated with

Rating

Single-dose administration of factor VIIa does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Single-dose administration of factor VIIa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Single-dose administration of factor VIIa will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3905212